Mitsubishi UFJ Asset Management UK Ltd. lowered its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 18.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,500 shares of the specialty pharmaceutical company’s stock after selling 5,000 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Supernus Pharmaceuticals were worth $745,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of SUPN. Financial Gravity Wealth Inc. acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $44,000. Advisor Group Inc. lifted its holdings in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 306 shares in the last quarter. Bremer Bank National Association acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $94,000. Huntington National Bank lifted its holdings in Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock worth $157,000 after buying an additional 4,028 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. acquired a new position in Supernus Pharmaceuticals in the 1st quarter worth $200,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.
Shares of Supernus Pharmaceuticals stock traded up $0.41 during trading on Friday, reaching $32.41. The company had a trading volume of 20,976 shares, compared to its average volume of 338,344. The firm has a market capitalization of $1.68 billion, a P/E ratio of 15.84, a price-to-earnings-growth ratio of 1.11 and a beta of 1.61. The firm’s fifty day simple moving average is $31.76. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.59 and a current ratio of 2.77. Supernus Pharmaceuticals Inc has a fifty-two week low of $29.60 and a fifty-two week high of $55.50.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.10). Supernus Pharmaceuticals had a net margin of 25.49% and a return on equity of 23.60%. The company had revenue of $85.50 million during the quarter, compared to analyst estimates of $102.26 million. During the same quarter last year, the company posted $0.49 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. On average, equities analysts forecast that Supernus Pharmaceuticals Inc will post 2.25 EPS for the current fiscal year.
SUPN has been the topic of a number of recent analyst reports. Mizuho reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, May 17th. BidaskClub lowered shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research note on Monday, June 24th. Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $107.00 target price on shares of Perrigo in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $55.57.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Story: Straddles
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.